Grants and Contributions:
Title:
ADME, Efficacy, and Mechanism of Action Studies for Oral and Topical Formulations of RLV-102
Agreement Number:
904288
Agreement Value:
$50,000.00
Agreement Date:
Apr 1, 2018 - Mar 31, 2019
Description:
This aim of this project is to determine the oral bioavailability and ADME properties of RLV-102 and develop a locally deliverable formulation (intestine/colon) for use as an oral therapeutic agent for inflammatory bowel disease.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V5R 3Y2
Reference Number:
172-2018-2019-Q3-904288
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
757837729
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 151 days.
Amendment Date
Oct 22, 2018
Recipient's Legal Name:
Resolvex Pharmaceuticals Inc.
Federal Riding Name:
Vancouver Kingsway
Federal Riding Number:
59038
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: